Poor
Poorly Aligned
Patient Risk:
Low
Summary
The claims repeatedly identify Repatha as alirocumab, whereas the label identifies its active ingredient as evolocumab, an IgG2 antibody. The label supports some product and indication details, but does not substantiate the extensive claims about patents, patent terms, exclusivity, market entry, or biosimilar development.
Category Scores
Accurate Statements
Repatha has drug-approved status.
The supplied prescribing information lists Repatha's indications and use.
The described Repatha formulation includes subcutaneous injection, concentration, excipients, and dosing information.
The label describes a 140 mg/mL solution for subcutaneous use, lists its excipients and devices, and provides recommended dosage regimens. It does not establish that a patent protects these features.
Unsupported Statements
The listed patents cover the claimed active ingredient, therapeutic indications, formulation, dosing schedule, or delivery device.
The label provides product, indication, and dosing information but does not discuss patent coverage or patent scope.
The stated patent filing, issue, and expiration dates; active status; and associated US, European Union, Canadian, or other jurisdictional patent terms.
The supplied label contains no patent dates, status, or jurisdictional patent information.
Patent expiration dates determine market protection, bar competing products, or keep generic competition out of the US market until 2025–2029.
The label does not discuss patent enforcement, market protection, competition, or market-entry dates.
Amgen, Roche, and Biogen are developing PCSK9 inhibitor biosimilars, their development stages, and their likely market-entry timing.
The label does not discuss biosimilar developers, development programs, or forecasts.
Repatha remains under FDA marketing exclusivity.
The label's indication information does not establish marketing exclusivity or its duration.
Evolocumab has its own set of patents.
The label does not discuss patents covering evolocumab.
The patent described as covering the active ingredient is US Patent 7,045,593.
Patent coverage is not addressed by the label; the label only identifies the active ingredient and its antibody class.
Contradictions
High
AI Statement
Repatha is alirocumab.
Label Reference
Section 11 identifies evolocumab as the active ingredient in Repatha.
Moderate
AI Statement
The anti-PCSK9 active ingredient covered by US Patent 7,045,593 is an IgG1 antibody.
Label Reference
Section 11 identifies evolocumab, Repatha's active ingredient, as an IgG2 antibody. The patent-coverage portion of the claim is not addressed by the label.
Moderate
AI Statement
Evolocumab is another, separate PCSK9 inhibitor and Repatha's sibling.
Label Reference
Sections 11 and 12.1 identify evolocumab as Repatha's active ingredient and describe its PCSK9 mechanism.
Important Omissions
The label identifies evolocumab as Repatha's active ingredient and states its approved uses: reducing major adverse cardiovascular events in adults at increased risk, and reducing LDL-C in the specified adult and pediatric populations.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims do not provide patient dosing or treatment instructions. However, misidentifying Repatha's active ingredient and antibody class could cause drug confusion.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Poorly Aligned
Primary Issue
The response incorrectly identifies Repatha as alirocumab and makes extensive patent, exclusivity, and biosimilar claims not supported by the supplied label.
Suggested Improvement
Correctly identify Repatha as evolocumab, an IgG2 antibody, and distinguish label-supported product and indication details from patent or market claims that cannot be verified from this prescribing information.